中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2014年
32期
2-3
,共2页
临床护理%微创治疗%自发性脑出血
臨床護理%微創治療%自髮性腦齣血
림상호리%미창치료%자발성뇌출혈
Minimally invasive therapy%Clinical nursing%Spontaneous cerebral hemorrhage
目的:探讨自发性脑出血的微创治疗及临床护理。方法将200例患者随机平均分成两组,保守治疗组100例,采用常规药物治疗,微创治疗组100例,在常规药物治疗的基础上,采用微创技术,对两组患者随访半年,根据自主生活能力来比较两组患者临床疗效,分析临床护理要求。结果两组患者通过微创、保守治疗后,随访半年,临床疗效比较发现,微创治疗组的临床治愈病例有45例,好转48例,死亡7例,而保守治疗组的治愈病例有19例,好转62例,死亡19例。结论微创治疗组临床疗效优于保守治疗组;做好手术全过程的护理工作,对于病情恢复意义重大。
目的:探討自髮性腦齣血的微創治療及臨床護理。方法將200例患者隨機平均分成兩組,保守治療組100例,採用常規藥物治療,微創治療組100例,在常規藥物治療的基礎上,採用微創技術,對兩組患者隨訪半年,根據自主生活能力來比較兩組患者臨床療效,分析臨床護理要求。結果兩組患者通過微創、保守治療後,隨訪半年,臨床療效比較髮現,微創治療組的臨床治愈病例有45例,好轉48例,死亡7例,而保守治療組的治愈病例有19例,好轉62例,死亡19例。結論微創治療組臨床療效優于保守治療組;做好手術全過程的護理工作,對于病情恢複意義重大。
목적:탐토자발성뇌출혈적미창치료급림상호리。방법장200례환자수궤평균분성량조,보수치료조100례,채용상규약물치료,미창치료조100례,재상규약물치료적기출상,채용미창기술,대량조환자수방반년,근거자주생활능력래비교량조환자림상료효,분석림상호리요구。결과량조환자통과미창、보수치료후,수방반년,림상료효비교발현,미창치료조적림상치유병례유45례,호전48례,사망7례,이보수치료조적치유병례유19례,호전62례,사망19례。결론미창치료조림상료효우우보수치료조;주호수술전과정적호리공작,대우병정회복의의중대。
Objective?To?investigate?the?spontaneous?intracerebral?hemorrhage?with?minimally?invasive?surgery?and?clinical?nursing.?Methods?200?patients?were?randomLy?divided?into?two?groups,?conservative?treatment?group?of?100?cases,?using?conventional?drug?therapy,?minimally?invasive?treatment?group?100?cases,?in?the?conventional?drug?treatment,?using?minimally?invasive?techniques,?the?two?groups?of?patients?were?followed?up?for?half?a?year,?according?to independent living ability to compare two groups of patients with clinical efifcacy, analysis of clinical nursing requirements. Results?The?two?groups?of patients through a minimally invasive, after conservative treatment, follow-up for half a year, comparison of the clinical efifcacy of minimally invasive treatment?group,?45?cases?were?cured,?48?cases?improved,?7?cases?of?death,?and?conservative?treatment?group?of?19?cases?were?cured,?62?cases?improved,?19?cases?of?death.?Conclusion?Minimally?invasive?treatment?group?were?superior?to?conservative?treatment?group;?good?operation?whole?process?nursing?work,?for the recovery of great signiifcance.